Print  |  Close

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)


Active: Yes
Cancer Type: Leukemia
Non-Hodgkin Lymphoma
NCT ID: NCT04035434
Trial Phases: Phase I Protocol IDs: CRSP-ONC-001 (primary)
NCI-2019-07066
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: CRISPR Therapeutics AG
NCI Full Details: http://clinicaltrials.gov/show/NCT04035434

Summary

This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of
CTX110 in subjects with relapsed or refractory B-cell malignancies.

Objectives

The study may enroll up to 143 subjects in total. CTX110 is a CD19-directed chimeric antigen
receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the
treatment of B cell malignancies. The cells are from healthy adult volunteer donors that are
genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short
palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA
and Cas9 nuclease).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.